Product Code: 978-1-68038-428-4
Next Generation Sequencing Market Summary
The global next-generation sequencing market size was estimated at USD 9.56 billion in 2024 and is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. This growth is driven by the increasing demand for advanced genomic research, rising applications of next-generation sequencing (NGS) in clinical diagnostics, and ongoing technological advancements in sequencing platforms.
Global Next-Generation Sequencing Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the next-generation sequencing market based on technology, product, workflow, end-use, and region.
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- WGS
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
- Others
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Platform
- Consumables
- Sample Preparation
- Target Enrichment
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Oncology
- Diagnostics and Screening
- Oncology Screening
- Sporadic Cancer
- Inherited Cancer
- Companion Diagnostics
- Other Diagnostics
- Research Studies
- Clinical Investigation
- Infectious Diseases
- Inherited Diseases
- Idiopathic Diseases
- Non-Communicable/Other Diseases
- Reproductive Health
- NIPT
- Aneuploidy
- Microdeletions
- PGT
- Newborn Genetic Screening
- Single Gene Analysis
- HLA Typing/Immune System Monitoring
- Metagenomics, Epidemiology & Drug Development
- Agrigenomics & Forensics
- Consumer Genomics
- Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- Pre-Sequencing
- Nucleic Acid Extraction
- Library Preparation
- Sequencing
- NGS Data Analysis
- NGS Primary Data Analysis
- NGS Secondary Data Analysis
- NGS Tertiary Data Analysis
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Other Users
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Technology Segment
- 1.1.2. Product Segment
- 1.1.3. Workflow Segment
- 1.1.4. Application Segment
- 1.1.5. End Use Segment
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objective
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Trends and Outlook
- 3.4. Market Dynamics
- 3.4.1. Market Drivers Analysis
- 3.4.1.1. Decreasing costs for genetic sequencing
- 3.4.1.2. Development of companion diagnostics and personalized medicine
- 3.4.1.3. Rising clinical opportunity for NGS technology
- 3.4.1.4. Technological advancements in cloud computing
- 3.4.2. Market Restraint Analysis
- 3.4.2.1. Lack of computational efficiency for data management
- 3.4.2.2. Non-value-based NGS reimbursement policy and regulation status
- 3.4.2.3. Challenges associated with NGS implementation
- 3.5. Market Analysis Tools
- 3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
- 3.5.2. Porter's Five Forces Analysis
Chapter 4. Technology Business Analysis
- 4.1. Segment Dashboard
- 4.2. Next Generation Sequencing Data Analysis Market: Technology Movement Analysis
- 4.3. Targeted Sequencing & Resequencing
- 4.3.1. Targeted Sequencing & Resequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 4.3.2. DNA-Based Targeted Sequencing & Resequencing
- 4.3.2.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
- 4.3.3. RNA-Based Targeted Sequencing & Resequencing
- 4.3.3.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
- 4.4. Whole Genome Sequencing
- 4.4.1. Whole Genome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 4.5. Whole Exome Sequencing
- 4.5.1. Whole Exome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 5. Product Business Analysis
- 5.1. Segment Dashboard
- 5.2. Next Generation Sequencing Data Analysis Market: Product Movement Analysis
- 5.3. Platforms
- 5.3.1. Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.3.2. Sequencing
- 5.3.2.1. Sequencing Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.3.3. Data Analysis
- 5.3.3.1. Data Analysis Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.4. Consumables
- 5.4.1. Consumables Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.4.2. Sample Preparation
- 5.4.2.1. Sample Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.4.3. Target Enrichment
- 5.4.3.1. Target Enrichment Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.4.4. Others
- 5.4.4.1. Others Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 6. Application Business Analysis
- 6.1. Segment Dashboard
- 6.2. Next Generation Sequencing Data Analysis Market: Application Movement Analysis
- 6.3. Oncology
- 6.3.1. Oncology Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.3.2. Diagnostics & Screening
- 6.3.2.1. Diagnostics & Screening Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 6.3.2.2. Oncology screening
- 6.3.2.2.1. Oncology Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.3.2.2.2. Sporadic Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.3.2.2.3. Inherited Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.3.2.3. Companion diagnostics
- 6.3.2.3.1. Companion Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.3.2.4. Other Diagnostics
- 6.3.2.4.1. Other Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.3.3. Research Studies
- 6.3.3.1. Research Studies Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.4. Clinical Investigation
- 6.4.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.4.2. Infectious Diseases
- 6.4.2.1. Infectious Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.4.3. Idiopathic Diseases
- 6.4.3.1. Idiopathic Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.4.4. Inherited Diseases
- 6.4.4.1. Inherited Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.4.5. Non-communicable/other Diseases
- 6.4.5.1. Reproductive Health Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5. Reproductive Health
- 6.5.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5.2. NIPT
- 6.5.2.1. NIPT Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5.2.2. Aneuploidy
- 6.5.2.2.1. Aneuploidy Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5.2.3. Microdeletions
- 6.5.2.3.1. Microdeletions Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5.3. PGT
- 6.5.3.1. PGT Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5.4. Newborn Genetic Screening
- 6.5.4.1. Newborn Genetic Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5.5. Single Gene Analysis Market
- 6.5.5.1. Single Gene Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.6. HLA Typing/Immune System Monitoring
- 6.6.1. HLA Typing/Immune System Monitoring Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.7. Metagenomics, Epidemiology & Drug Development
- 6.7.1. Metagenomics, Epidemiology & Drug Development Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.8. Agrigenomics & Forensics
- 6.8.1. Agrigenomics & Forensics Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.9. Consumer Genomics
- 6.9.1. Consumer Genomics Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 7. Workflow Business Analysis
- 7.1. Segment Dashboard
- 7.2. Next Generation Sequencing Data Analysis Market: Workflow Movement Analysis
- 7.3. Presequencing
- 7.3.1. Presequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.3.2. Nucleic Acid Extraction
- 7.3.2.1. Nucleic Acid Extraction Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.3.3. Library Preparation
- 7.3.3.1. Library Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.4. Sequencing
- 7.4.1. Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5. Data Analysis
- 7.5.1. Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5.2. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5.2.1. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5.3. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5.3.1. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5.4. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5.4.1. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 8. End Use Business Analysis
- 8.1. Segment Dashboard
- 8.2. Next Generation Sequencing Market: End - Use Movement Analysis
- 8.3. Academic Research
- 8.3.1. Academic Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 8.4. Clinical Research
- 8.4.1. Clinical Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 8.5. Hospitals & Clinics
- 8.5.1. Hospitals & Clinics Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 8.6. Pharmaceutical & Biotech Entities
- 8.6.1. Pharmaceutical & Biotech Entities Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 8.7. Other Users
- 8.7.1. Other Users Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 9. Regional Business Analysis
- 9.1. Next Generation Sequencing Market Share By Region, 2024 & 2033
- 9.2. North America
- 9.2.1. North America next generation sequencing market, 2021 - 2033 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key country dynamics
- 9.2.2.2. U.S. next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.2.3. Target disease prevalence
- 9.2.2.4. Competitive scenario
- 9.2.2.5. Regulatory framework
- 9.2.2.6. Reimbursement scenario
- 9.2.3. Canada
- 9.2.3.1. Key country dynamics
- 9.2.3.2. Canada next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.3.3. Target disease prevalence
- 9.2.3.4. Competitive scenario
- 9.2.3.5. Regulatory framework
- 9.2.3.6. Reimbursement scenario
- 9.2.4. Mexico
- 9.2.4.1. Key country dynamics
- 9.2.4.2. Mexico next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.4.3. Target disease prevalence
- 9.2.4.4. Competitive scenario
- 9.2.4.5. Regulatory framework
- 9.2.4.6. Reimbursement scenario
- 9.2.5. Europe
- 9.2.6. Europe Next Generation Sequencing market, 2021 - 2033 (USD Million)
- 9.2.7. Germany
- 9.2.7.1. Key country dynamics
- 9.2.7.2. Germany next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.7.3. Target disease prevalence
- 9.2.7.4. Competitive scenario
- 9.2.7.5. Regulatory framework
- 9.2.7.6. Reimbursement scenario
- 9.2.8. UK
- 9.2.8.1. Key country dynamics
- 9.2.8.2. UK next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.8.3. Target disease prevalence
- 9.2.8.4. Competitive scenario
- 9.2.8.5. Regulatory framework
- 9.2.8.6. Reimbursement scenario
- 9.2.9. France
- 9.2.9.1. Key country dynamics
- 9.2.9.2. France next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.9.3. Target disease prevalence
- 9.2.9.4. Competitive scenario
- 9.2.9.5. Regulatory framework
- 9.2.9.6. Reimbursement scenario
- 9.2.10. Italy
- 9.2.10.1. Key country dynamics
- 9.2.10.2. Italy next generation sequencing (NGS) market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.10.3. Target disease prevalence
- 9.2.10.4. Competitive scenario
- 9.2.10.5. Regulatory framework
- 9.2.10.6. Reimbursement scenario
- 9.2.11. Spain
- 9.2.11.1. Key country dynamics
- 9.2.11.2. Spain next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.11.3. Target disease prevalence
- 9.2.11.4. Competitive scenario
- 9.2.11.5. Regulatory framework
- 9.2.11.6. Reimbursement scenario
- 9.2.12. Denmark
- 9.2.12.1. Key country dynamics
- 9.2.12.2. Denmark next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.12.3. Target disease prevalence
- 9.2.12.4. Competitive scenario
- 9.2.12.5. Regulatory framework
- 9.2.12.6. Reimbursement scenario
- 9.2.13. Sweden
- 9.2.13.1. Key country dynamics
- 9.2.13.2. Sweden next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.13.3. Target disease prevalence
- 9.2.13.4. Competitive scenario
- 9.2.13.5. Regulatory framework
- 9.2.13.6. Reimbursement scenario
- 9.2.14. Norway
- 9.2.14.1. Key country dynamics
- 9.2.14.2. Norway next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.2.14.3. Target disease prevalence
- 9.2.14.4. Competitive scenario
- 9.2.14.5. Regulatory framework
- 9.2.14.6. Reimbursement scenario
- 9.3. Asia Pacific
- 9.3.1. Asia Pacific next generation sequencing market, 2021 - 2033 (USD Million)
- 9.3.2. Japan
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Japan next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.3.2.3. Target disease prevalence
- 9.3.2.4. Competitive scenario
- 9.3.2.5. Regulatory framework
- 9.3.2.6. Reimbursement scenario
- 9.3.3. China
- 9.3.3.1. Key country dynamics
- 9.3.3.2. China next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.3.3.3. Target disease prevalence
- 9.3.3.4. Competitive scenario
- 9.3.3.5. Regulatory framework
- 9.3.3.6. Reimbursement scenario
- 9.3.4. India
- 9.3.4.1. Key country dynamics
- 9.3.4.2. India next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.3.4.3. Target disease prevalence
- 9.3.4.4. Competitive scenario
- 9.3.4.5. Regulatory framework
- 9.3.4.6. Reimbursement scenario
- 9.3.5. South Korea
- 9.3.5.1. Key country dynamics
- 9.3.5.2. South Korea next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.3.5.3. Target disease prevalence
- 9.3.5.4. Competitive scenario
- 9.3.5.5. Regulatory framework
- 9.3.5.6. Reimbursement scenario
- 9.3.6. Australia
- 9.3.6.1. Key country dynamics
- 9.3.6.2. Australia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.3.6.3. Target disease prevalence
- 9.3.6.4. Competitive scenario
- 9.3.6.5. Regulatory framework
- 9.3.6.6. Reimbursement scenario
- 9.3.7. Thailand
- 9.3.7.1. Key country dynamics
- 9.3.7.2. Thailand next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.3.7.3. Target disease prevalence
- 9.3.7.4. Competitive scenario
- 9.3.7.5. Regulatory framework
- 9.3.7.6. Reimbursement scenario
- 9.4. Latin America
- 9.4.1. Latin America next generation sequencing market, 2021 - 2033 (USD Million)
- 9.4.2. Brazil
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Brazil next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.4.2.3. Target disease prevalence
- 9.4.2.4. Competitive scenario
- 9.4.2.5. Regulatory framework
- 9.4.2.6. Reimbursement scenario
- 9.4.3. Argentina
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Argentina next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.4.3.3. Target disease prevalence
- 9.4.3.4. Competitive scenario
- 9.4.3.5. Regulatory framework
- 9.4.3.6. Reimbursement scenario
- 9.5. MEA
- 9.5.1. MEA next generation sequencing market, 2021 - 2033 (USD Million)
- 9.5.2. South Africa
- 9.5.2.1. Key country dynamics
- 9.5.2.2. South Africa next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.5.2.3. Target disease prevalence
- 9.5.2.4. Competitive scenario
- 9.5.2.5. Regulatory framework
- 9.5.2.6. Reimbursement scenario
- 9.5.3. Saudi Arabia
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Saudi Arabia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.5.3.3. Target disease prevalence
- 9.5.3.4. Competitive scenario
- 9.5.3.5. Regulatory framework
- 9.5.3.6. Reimbursement scenario
- 9.5.4. UAE
- 9.5.4.1. Key country dynamics
- 9.5.4.2. UAE next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.5.4.3. Target disease prevalence
- 9.5.4.4. Competitive scenario
- 9.5.4.5. Regulatory framework
- 9.5.4.6. Reimbursement scenario
- 9.5.5. Kuwait
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Kuwait next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
- 9.5.5.3. Target disease prevalence
- 9.5.5.4. Competitive scenario
- 9.5.5.5. Regulatory framework
- 9.5.5.6. Reimbursement scenario
Chapter 10. Competitive Landscape
- 10.1. Company/Competition Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Position Analysis, 2024
- 10.4. Company Profiles/Listing
- 10.4.1. Illumina
- 10.4.1.1. Company overview
- 10.4.1.2. Financial performance
- 10.4.1.3. Product benchmarking
- 10.4.1.4. Strategic initiatives
- 10.4.2. F. Hoffman-La Roche Ltd.
- 10.4.2.1. Company overview
- 10.4.2.2. Financial performance
- 10.4.2.3. Product benchmarking
- 10.4.2.4. Strategic initiatives
- 10.4.3. QIAGEN
- 10.4.3.1. Company overview
- 10.4.3.2. Financial performance
- 10.4.3.3. Product benchmarking
- 10.4.3.4. Strategic initiatives
- 10.4.4. Thermo Fisher Scientific, Inc.
- 10.4.4.1. Company overview
- 10.4.4.2. Financial performance
- 10.4.4.3. Product benchmarking
- 10.4.4.4. Strategic initiatives
- 10.4.5. Bio-Rad Laboratories, Inc.
- 10.4.5.1. Company overview
- 10.4.5.2. Financial performance
- 10.4.5.3. Product benchmarking
- 10.4.5.4. Strategic initiatives
- 10.4.6. Oxford Nanopore Technologies
- 10.4.6.1. Company overview
- 10.4.6.2. Financial performance
- 10.4.6.3. Product benchmarking
- 10.4.6.4. Strategic initiatives
- 10.4.7. Revvity, Inc.
- 10.4.7.1. Company overview
- 10.4.7.2. Financial performance
- 10.4.7.3. Product benchmarking
- 10.4.7.4. Strategic initiatives
- 10.4.8. PacBio
- 10.4.8.1. Company overview
- 10.4.8.2. Financial performance
- 10.4.8.3. Product benchmarking
- 10.4.8.4. Strategic initiatives
- 10.4.9. Merk KGaA
- 10.4.9.1. Company overview
- 10.4.9.2. Financial performance
- 10.4.9.3. Product benchmarking
- 10.4.9.4. Strategic initiatives
- 10.4.10. BGI
- 10.4.10.1. Company overview
- 10.4.10.2. Financial performance
- 10.4.10.3. Product benchmarking
- 10.4.10.4. Strategic initiatives